Pneumococcal conjugate vaccines |
Prevention of nasopharyngeal carriage [7, 8] |
Reduction of diseases in unvaccinated populations (herd or indirect effect) [9] |
Reduction of antimicrobial resistance and antimicrobial use [10] |
Haemophilus influenzae type B, meningococcal disease, measles; viral vaccines, such as influenza, respiratory syncytial virus, and measles |
Reduced antimicrobial use, including use for secondary infections, and reduced antimicrobial resistance [11–13] |
Reducing inappropriate antibiotic prescriptions [14] |
Influenza |
Reduced antimicrobial use and antimicrobial resistance [15] |
Decrease in cardiovascular events, i.e. myocardial infarction, stroke, cardiac insufficiency [16–18] |
Hepatitis B |
Cirrhosis and liver cancer (due to prevention of chronic carriage) [19] |
Human papilloma virus (HPV) |
HPV-related cancers (due to prevention of chronic carriage) in both female and male [20] |
Vertical transmission (neonatal) [21] |